Copenhagen, Denmark, November 14, 2024 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of Directors. Gerd Zettlmeissl, the previous Chair, who was instrumental in the transition of MinervaX from a […]
MinervaX scaling up supply of novel GBS vaccine, ahead of phase III studies Wacker Biotech to manufacture active vaccine protein ingredients and prepare for commercial supply after regulatory approval Vaccine to address the unmet medical burden of GBS, both by maternal vaccination to prevent adverse pregnancy outcomes and life-threatening infections in infants and by vaccination […]
Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated in Q4, 2023 Copenhagen, Denmark, 27 June 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today […]
A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the […]
In April 2020 Kate Bingham was invited by Sir Patrick Vallance, the government’s chief scientific advisor, to join the Vaccine Expert Advisory Group. In May 2020 she was appointed Chair of the UK Vaccine Taskforce (VTF), an idea originated by Patrick Vallance, reporting to the Prime Minister to lead UK efforts to find and manufacture […]
